Management of Advanced Heart Failure in the Elderly: Ethics, Economics, and Resource Allocation in the Technological Era

Significant strides have been made in the durability, portability, and safety of mechanical circulatory support devices (MCS). Although transplant is considered the standard treatment for advanced heart failure, limits in organ availability leave a much larger pool of recipients in need versus donor...

Full description

Bibliographic Details
Main Authors: Keith M. Swetz, John M. Stulak, Shannon M. Dunlay, Ellin F. Gafford
Format: Article
Language:English
Published: Hindawi Limited 2012-01-01
Series:Cardiology Research and Practice
Online Access:http://dx.doi.org/10.1155/2012/524961
id doaj-089792cf53a748a0983cd7fab92fc2e6
record_format Article
spelling doaj-089792cf53a748a0983cd7fab92fc2e62020-11-24T22:08:32ZengHindawi LimitedCardiology Research and Practice2090-80162090-05972012-01-01201210.1155/2012/524961524961Management of Advanced Heart Failure in the Elderly: Ethics, Economics, and Resource Allocation in the Technological EraKeith M. Swetz0John M. Stulak1Shannon M. Dunlay2Ellin F. Gafford3Division of General Internal Medicine, Department of Medicine, Section of Palliative Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USADivision of Cardiovascular Surgery, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USADivision of Cardiovascular Medicine, Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USAPalliative Medicine, Ross Heart Hospital, Wexner Medical Center, The Ohio State University, Columbus, OH 43210, USASignificant strides have been made in the durability, portability, and safety of mechanical circulatory support devices (MCS). Although transplant is considered the standard treatment for advanced heart failure, limits in organ availability leave a much larger pool of recipients in need versus donors. MCS is used as bridge to transplantation and as destination therapy (DT) for patients who will have MCS as their final invasive therapy with transplant not being an option. Despite improvements in quality of life (QOL) and survival, defining the optimal candidate for DT may raise questions regarding the economics of this approach as well as ethical concerns regarding just distribution of goods and services. This paper highlights some of the key ethical issues related to justice and the costs of life-prolonging therapies with respect to resource allocations. Available literature, current debates, and future directions are discussed herein.http://dx.doi.org/10.1155/2012/524961
collection DOAJ
language English
format Article
sources DOAJ
author Keith M. Swetz
John M. Stulak
Shannon M. Dunlay
Ellin F. Gafford
spellingShingle Keith M. Swetz
John M. Stulak
Shannon M. Dunlay
Ellin F. Gafford
Management of Advanced Heart Failure in the Elderly: Ethics, Economics, and Resource Allocation in the Technological Era
Cardiology Research and Practice
author_facet Keith M. Swetz
John M. Stulak
Shannon M. Dunlay
Ellin F. Gafford
author_sort Keith M. Swetz
title Management of Advanced Heart Failure in the Elderly: Ethics, Economics, and Resource Allocation in the Technological Era
title_short Management of Advanced Heart Failure in the Elderly: Ethics, Economics, and Resource Allocation in the Technological Era
title_full Management of Advanced Heart Failure in the Elderly: Ethics, Economics, and Resource Allocation in the Technological Era
title_fullStr Management of Advanced Heart Failure in the Elderly: Ethics, Economics, and Resource Allocation in the Technological Era
title_full_unstemmed Management of Advanced Heart Failure in the Elderly: Ethics, Economics, and Resource Allocation in the Technological Era
title_sort management of advanced heart failure in the elderly: ethics, economics, and resource allocation in the technological era
publisher Hindawi Limited
series Cardiology Research and Practice
issn 2090-8016
2090-0597
publishDate 2012-01-01
description Significant strides have been made in the durability, portability, and safety of mechanical circulatory support devices (MCS). Although transplant is considered the standard treatment for advanced heart failure, limits in organ availability leave a much larger pool of recipients in need versus donors. MCS is used as bridge to transplantation and as destination therapy (DT) for patients who will have MCS as their final invasive therapy with transplant not being an option. Despite improvements in quality of life (QOL) and survival, defining the optimal candidate for DT may raise questions regarding the economics of this approach as well as ethical concerns regarding just distribution of goods and services. This paper highlights some of the key ethical issues related to justice and the costs of life-prolonging therapies with respect to resource allocations. Available literature, current debates, and future directions are discussed herein.
url http://dx.doi.org/10.1155/2012/524961
work_keys_str_mv AT keithmswetz managementofadvancedheartfailureintheelderlyethicseconomicsandresourceallocationinthetechnologicalera
AT johnmstulak managementofadvancedheartfailureintheelderlyethicseconomicsandresourceallocationinthetechnologicalera
AT shannonmdunlay managementofadvancedheartfailureintheelderlyethicseconomicsandresourceallocationinthetechnologicalera
AT ellinfgafford managementofadvancedheartfailureintheelderlyethicseconomicsandresourceallocationinthetechnologicalera
_version_ 1725816119705468928